Loading quotes...

Forecast

The analysts' average price target is €13.42 (+39.07%). The median is €13.42 (+39.07%).

Buy	10
Hold	1
Sell	0

News Go to news feed

Xeris Biopharma outlines growth plan at H.C. Wainwright conference

Xeris Biopharma presented its strategic vision, emphasizing growth from Recorlev and a planned phase-3 study for XP8121 in hypothyroidism with gastrointestinal absorption disorders. The company expects revenue growth of around 40% year over year and reports gross margins of about 85% as well as positive adjusted EBITDA in the prior year. Market potential is cited at $1–3 billion for XP8121 and about $1 billion for Recorlev; commercialization is to be driven by expanded sales activities and clinician training. Xeris stresses a self-funded business model but sees competitive pressure in an evolving market. » More on de.investing.com
Xeris Pharmaceuticals reaches 52-week high at $8.02 after strong quarterly results and patent

Xeris Pharmaceuticals stock rose to a 52-week high of $8.02 with a market capitalization of about $1.28 billion; however, technical indicators show an overbought level. In Q2 2025 Xeris beat EPS expectations (-$0.01 vs. -$0.03) and reported revenue of $71.5 million, supported by revenue growth of 35.6% year over year. Xeris Biopharma Holdings also received a new patent for Recorlev through March 2040, and H.C. Wainwright initiated coverage with a buy rating and a $10.00 price target. » More on de.investing.com

Financials

In the last quarter, Xeris Pharmaceuticals Aktie had revenue of €80.7M and net profit of -€27.25M

(EUR)	June 2026	YoY
Revenue	80.7M	32.96%
Gross profit	69.74M	44.38%
Net profit	-27.25M	1,565.96%
EBITDA	-18.35M	351.69%

Fundamentals

Metric	Value
Market capitalization	€1.73B
Number of shares	182.32M
52-week high/low	€10.21 - €4.70
Dividends	No
Beta	0.84
P/E ratio	-109.58
PEG ratio	0.01
P/B ratio	-188.91
P/S ratio	5.78

Company profile

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.